Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 163
Filter
1.
J Clin Pathol ; 65(3): 267-71, 2012 Mar.
Article in English | MEDLINE | ID: mdl-22135026

ABSTRACT

BACKGROUND: The examination of ciliary ultrastructure in a nasal sample remains a definitive diagnostic test for primary ciliary dyskinesia (PCD). METHODS: The quantitative assessment of ciliary ultrastructure in the diagnosis of PCD over a 20-year period was reviewed. RESULTS: During this period, 1182 patients were referred for ciliary ultrastructural analysis, 242 (20%) of whom were confirmed as having the disease. The two main causes of PCD identified were a lack of outer dynein arms (43%) and a lack of both inner and outer dynein arms (24%). Other causes included transposition, radial spoke and inner dynein arm defects. No specific ultrastructural defects were detected in 33 patients (3%) diagnosed as having PCD on the basis of their clinical features and screening tests that included a low nasal nitric oxide concentration or slow saccharine clearance and abnormal ciliary beat frequency or pattern. CONCLUSIONS: Electron microscopy analysis can confirm but does not always exclude a diagnosis of PCD.


Subject(s)
Axoneme/ultrastructure , Kartagener Syndrome/diagnosis , Microscopy, Electron, Transmission , Nasal Mucosa/ultrastructure , Adolescent , Adult , Aged , Aged, 80 and over , Biopsy , Child , Child, Preschool , Cilia/ultrastructure , Humans , Infant , Infant, Newborn , Kartagener Syndrome/metabolism , Kartagener Syndrome/pathology , Middle Aged , Nasal Mucosa/metabolism , Nitric Oxide/metabolism , Predictive Value of Tests , Prognosis , Saccharin , Time Factors , Young Adult
2.
Histopathology ; 53(2): 218-23, 2008 Aug.
Article in English | MEDLINE | ID: mdl-18752504

ABSTRACT

AIMS: To test the reproducibility of the current World Health Organization (WHO) classification of thymic epithelial tumours and to determine the level of interobserver variation within a group of pathologists, all with experience and expertise in thoracic pathology. METHODS AND RESULTS: Ninety-five thymic tumours were circulated to a group of 17 pathologists in the UK and The Netherlands over a 1-year period. Participants were asked to classify them according to WHO criteria. The diagnoses were subjected to statistical analysis and kappa values calculated. The overall level of agreement was moderate (kappa 0.45). When the categories were reduced in number by creating two groups, (A + AB + B1 + B2 and B3 + C), the level of agreement increased to 0.62. An alternative grouping (A + AB + B1 and B2 + B3 + C) increased it slightly further. The best agreement was in tumour types A and AB. Difficulties arose in distinguishing B1 tumours from B2 tumours and B2 tumours from B3 tumours. CONCLUSIONS: Although the WHO system describes a number of well-defined tumour types with clear diagnostic criteria, the overall level of agreement was moderate and improved if some groups were amalgamated.


Subject(s)
Severity of Illness Index , Thymus Neoplasms/classification , World Health Organization , Humans , Observer Variation , Prognosis , Reproducibility of Results , Thymoma/classification , Thymoma/epidemiology , Thymoma/pathology , Thymus Neoplasms/diagnosis , Thymus Neoplasms/epidemiology , Thymus Neoplasms/pathology
3.
Thorax ; 59(6): 500-5, 2004 Jun.
Article in English | MEDLINE | ID: mdl-15170033

ABSTRACT

BACKGROUND: There have been few inter-observer studies of diffuse parenchymal lung disease (DPLD), but the recent ATS/ERS consensus classification provides a basis for such a study. METHODS: A method for categorising numerically the percentage likelihood of these differential diagnoses was developed, and the diagnostic confidence of pathologists using this classification and the reproducibility of their diagnoses were assessed. RESULTS: The overall kappa coefficient of agreement for the first choice diagnosis was 0.38 (n = 133 biopsies), increasing to 0.43 for patients (n = 83) with multiple biopsies. Weighted kappa coefficients of agreement, quantifying the level of probability of individual diagnoses, were moderate to good (mean 0.58, range 0.40-0.75). However, in 18% of biopsy specimens the diagnosis was given with low confidence. Over 50% of inter-observer variation related to the diagnosis of non-specific interstitial pneumonia and, in particular, its distinction from usual interstitial pneumonia. CONCLUSION: These results show that the ATS/ERS classification can be applied reproducibly by pathologists who evaluate DPLD routinely, and support the practice of taking multiple biopsy specimens.


Subject(s)
Clinical Competence/standards , Lung Diseases/pathology , Pathology, Clinical , Biopsy/methods , Diagnosis, Differential , Humans , Observer Variation , Reproducibility of Results
4.
Histopathology ; 41(5): 404-13, 2002 Nov.
Article in English | MEDLINE | ID: mdl-12405908

ABSTRACT

AIMS: Sclerosing haemangiomas typically comprise a mixture of four architectural patterns (papillary, sclerotic, solid and haemorrhagic) and two cell types, eosinophilic cuboidal epithelial lining cells and sheets of rounded cells with either eosinophilic or clear cytoplasm. In most instances, recognition of these architectural and cytological features provides sufficient evidence for diagnosis. This study presents and discusses the histogenesis of four cases where difficulties in diagnosis were encountered, and reports the value of the antibody TTF-1 in making the diagnosis. METHODS AND RESULTS: Four cases with focal areas reminiscent of sclerosing haemangioma were reviewed and immunostained with an antibody panel including antibodies to TTF-1 and surfactant apoprotein A. Of these, one case was classified as sclerosing haemangioma combined with typical carcinoid, in which there was a mediastinal lymph node metastasis solely comprising the solid component of sclerosing haemangioma. The second was classified as an alveolar adenoma with sclerosing haemangioma-like areas. In the remaining two cases, diagnosis was confounded by presentation with predominantly cystic masses, the largest 70 mm in diameter. Immunohistochemically, TTF-1 was of greater value than surfactant apoprotein, in particular in identifying the solid component of sclerosing haemangioma when this was solely present. CONCLUSION: Sclerosing haemangiomas should be considered in the differential diagnosis of cystic pulmonary masses. They may also present histologically as combined tumours and metastasize to mediastinal nodes, indicating an, albeit low, malignant potential. TTF-1 is a valuable antibody in identifying the presence of a sclerosing haemangioma when typical features are absent.


Subject(s)
Hemangioma/diagnosis , Lung Neoplasms/diagnosis , Nuclear Proteins , Transcription Factors , Aged , Biomarkers, Tumor/metabolism , Cysts/diagnosis , Cysts/metabolism , Diagnosis, Differential , Female , Hemangioma/metabolism , Humans , Immunoenzyme Techniques , Lung Diseases/diagnosis , Lung Diseases/metabolism , Lung Neoplasms/metabolism , Male , Middle Aged , Nuclear Proteins/analysis , Radiography, Thoracic , Sclerosis/metabolism , Sclerosis/pathology , Thyroid Nuclear Factor 1 , Tomography, X-Ray Computed , Transcription Factors/analysis
5.
Histopathology ; 41(3): 263-5, 2002 Sep.
Article in English | MEDLINE | ID: mdl-12207789

ABSTRACT

AIMS: To report the first case of respiratory failure due to micronodular type II pneumocyte hyperplasia. METHODS AND RESULTS: Biopsy, explant and autopsy material from a 16-year-old girl, a smoker, with no personal or family history of tuberous sclerosis, who died following lung transplantation necessitated by progressive respiratory failure, was evaluated histologically. Micronodular pneumocyte hyperplasia was identified histologically as the cause of the respiratory failure. Foci of hyperplastic type II pneumocytes measuring up to 4 mm were widely scattered through the lungs. The hyperplastic cells had abundant eosinophilic cytoplasm, vesicular nuclei and prominent nucleoli. Immunohistochemistry showed that they stained for cytokeratins AE1, AE3 and CAM 5.2 and for epithelial membrane antigen (EMA), but not for carcinoembryonic antigen (CEA), S100, smooth muscle actin, CD68 and HMB-45. CONCLUSIONS: Although micronodular type II pneumocyte hyperplasia is usually of no clinical significance, in our patient the process was so florid as to cause respiratory failure, which was severe enough to necessitate lung transplantation.


Subject(s)
Hyperplasia/pathology , Lung Diseases/pathology , Lung Diseases/physiopathology , Adolescent , Diagnosis, Differential , Fatal Outcome , Female , Humans , Lung Diseases/complications , Lung Diseases/metabolism , Lung Diseases/surgery , Lung Transplantation , Respiratory Insufficiency/etiology
6.
Am J Surg Pathol ; 25(12): 1508-14, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11717540

ABSTRACT

Epithelial-myoepithelial carcinomas are very rare in the lung, and little is known about the relationship of their histologic features to prognosis. We describe five primary pulmonary epithelial-myoepithelial carcinomas with details on clinical presentation, histology, and immunohistochemical profiles. We also reviewed the literature to detail further their prognosis. The patients' ages ranged from 33 to 57 years (average 51 years). The tumors were all endobronchial and the patients presented with symptoms or imaging features of airway obstruction. The tumors were completely resected; none showed nodal involvement. All five patients are alive and free of disease 4 months to 8 years (average 4.2 years) after surgery. Four tumors showed a mixed pattern of glands lined by a dual layer of cells and solid sheets of either spindle cells or clear cells, the glandular and solid components being present in variable proportions. The fifth tumor comprised purely spindle cells. The mitotic rate was <1/20 high power fields in both the glandular and spindle/clear cell components. In one case there was focal nuclear pleomorphism. The inner layer of the glands stained for cytokeratins and epithelial membrane antigen, and the outer layer for S-100 and smooth muscle actin. In one case the spindle cells stained for CD34. A review of published cases shows the majority of tumors behave in an indolent fashion, the rare aggressive tumors being predominantly myoepitheliomatous. Nevertheless, the term epithelial-myoepithelial carcinoma is preferred because of their malignant potential. A high mitotic rate, tumoral necrosis, and nuclear pleomorphism appear to be adverse prognostic factors.


Subject(s)
Bronchial Neoplasms/pathology , Carcinoma/pathology , Actins/analysis , Adult , Antigens, CD34/analysis , Biomarkers, Tumor/analysis , Bronchial Neoplasms/chemistry , Carcinoma/chemistry , Female , Humans , Immunohistochemistry , Ki-67 Antigen/analysis , Male , Middle Aged , Mitotic Index , Mucin-1/analysis , Prognosis , S100 Proteins/analysis
7.
Histopathology ; 38(3): 202-8, 2001 Mar.
Article in English | MEDLINE | ID: mdl-11260299

ABSTRACT

AIMS: Although many workers have graded pre-invasive squamous lesions arising in the bronchus, there has been no consensus classification system until the latest edition of the WHO/IASLC histological classification of pulmonary and pleural tumours. Because the value of any such system is dependent on its reproducibility, we have circulated a series of such lesions to a panel of histopathologists to assess interobserver and intra-observer variation when the WHO/IASLC classification was applied. METHODS AND RESULTS: Colour transparencies of 28 pre-invasive squamous lesions were assessed by six histopathologists (two with a special interest in pulmonary pathology, two generalists and two trainees) on three separate occasions over a period of 3 months, using the criteria of the WHO/IASLC (mild, moderate and severe dysplasia, and in-situ carcinoma). An additional category of metaplasia was added for those cases that showed no dysplasia. Weighted kappa coefficents of agreement (K(w)) were used to evaluate paired observations with a standard quadratic weighting being employed, such that kappa coefficients corresponded to intra-class correlation coefficients. Wilcoxon's sign-ranked test was used to measure the statistical significance of group trends, when comparing kappa values for the three grading systems. Various 3-point systems were also assessed, through combination of the above groups. Intra-observer agreement was substantially better than interobserver variation (mean: 0.71 vs. 0.55). Between the various pathologist groups, inter-observer variation was relatively minor, although intra-observer variation was higher within the trainee pathologist group. Using weighted kappa values, there was no significant difference in either inter-observer or intra-observer agreement between the five point grading system and a 3-point system of metaplasia/mild, moderate and severe/in-situ grades. However, there was a significant increase in variation when a 3-point system of metaplasia/mild, moderate/severe and in-situ carcinoma was used. CONCLUSION: This study shows levels of interobserver and intra-observer variation similar to those found in other grading systems in histopathology, with no significant decrease in variability found by abridging the system. The WHO/IASLC system is therefore recommended for future use in both clinical and research fields.


Subject(s)
Bronchial Neoplasms/pathology , Neoplasms, Squamous Cell/pathology , Bronchial Neoplasms/classification , Humans , Metaplasia/pathology , Neoplasms, Squamous Cell/classification , Observer Variation , Precancerous Conditions/pathology , Reproducibility of Results
8.
Eur Respir J ; 18(6): 1059-68, 2001 Dec.
Article in English | MEDLINE | ID: mdl-11829087

ABSTRACT

Tumour classification systems provide the foundation for tumour diagnosis and patient therapy and a critical basis for epidemiological and clinical studies. This updated classification was developed with the aim to adhere to the principles of reproducibility, clinical significance, and simplicity in order to minimize the number of unclassifiable lesions. Major changes in the revised classification as compared to the previous one (WHO 1981) include the addition of two pre-invasive lesions to squamous dysplasia and carcinoma in situ; atypical adenomatous hyperplasia and diffuse idiopathic pulmonary neuroendocrine cell hyperplasia. Another change is the subclassification of adenocarcinoma: the definition of bronchioalveolar carcinoma has been restricted to noninvasive tumours. There has been substantial evolution of concepts in neuroendocrine lung tumour classification. Large cell neuroendocrine carcinoma (LCNEC) is now recognized as a histologically high grade non small cell carcinoma showing histopathological features of neuroendocrine differentiation as well as immunohistochemical neuroendocrine markers. The large cell carcinoma class has been enriched with several variants, including the LCNEC and the basaloid carcinoma, both with a dismal prognosis. Finally, a new class was defined called carcinoma with pleomorphic, sarcomatoid, or sarcomatous elements, which brings together a number of proliferations characterized by a spectrum of epithelial to mesenchymal differentiation. Immunohistochemistry and electron microscopy are invaluable techniques for diagnosis and subclassification, but our intention was to render the classification simple and practical to every surgical laboratory, so that most lung tumours could be classified by light microscopic criteria.


Subject(s)
Lung Neoplasms/classification , World Health Organization , Adenocarcinoma/classification , Adenocarcinoma/pathology , Carcinoma/classification , Carcinoma/pathology , Humans , Lung Neoplasms/pathology , Precancerous Conditions/pathology
9.
Mod Pathol ; 13(2): 107-12, 2000 Feb.
Article in English | MEDLINE | ID: mdl-10697265

ABSTRACT

Until recently, the standard approach of most laboratories in distinguishing epithelioid pleural mesothelioma from metastatic adenocarcinoma has been a negative result from a panel of adenocarcinoma-associated antibodies. However, several "mesothelium-associated" antibodies have been proposed as useful in this situation, and we have applied four of these putative mesothelioma markers--thrombomodulin, cytokeratin 5/6, calretinin, and CD44H--to a series of 61 epithelioid pleural mesotheliomas and 63 metastatic adenocarcinomas with known primary sites (lung = 19; breast = 21; ovary = 6; colon = 10; kidney = 4; uterus, epididymis, pancreas = 1 case each). Of the mesotheliomas, 55 of 61 (90%) stained for thrombomodulin, 56 of 61 (92%) for cytokeratin 5/6, 47 of 51 cases (92%) were positive for calretinin, and 39 of 43 (91%) were positive for CD44H. Of the metastatic adenocarcinomas, 12 of 63 (19%) cases were positive for thrombomodulin, 9 of 63 (14%) were positive for CK5/6, and 27 of 60 (45%) were positive for CD44H. With calretinin, only 1 case of 59 (2%) showed positive nuclear staining. All four antibodies stained reactive mesothelium; thrombomodulin also stained endothelium; and CD44H variably stained lymphocytes, macrophages, and fibroblasts. We conclude that all four antibodies show high sensitivity for epithelioid mesothelioma, but only calretinin (98%), cytokeratin 5/6 (86%), and thrombomodulin (81%) show sufficient specificity for practical use in this situation.


Subject(s)
Adenocarcinoma/diagnosis , Antibodies, Neoplasm , Antigens, Neoplasm/immunology , Mesothelioma/diagnosis , Pleural Neoplasms/diagnosis , Adenocarcinoma/secondary , Calbindin 2 , Diagnosis, Differential , Humans , Hyaluronan Receptors/immunology , Immunoenzyme Techniques , Keratins/immunology , Mesothelioma/pathology , Pleural Neoplasms/secondary , S100 Calcium Binding Protein G/immunology , Sensitivity and Specificity , Thrombomodulin/immunology
10.
J Pathol ; 189(2): 251-7, 1999 Oct.
Article in English | MEDLINE | ID: mdl-10547583

ABSTRACT

Distinguishing malignant mesothelioma from reactive mesothelial hyperplasia and reactive fibrosis can be a diagnostic problem in small pleural biopsies, made more difficult by the recent recognition of mesothelioma-in-situ. Antibodies to epithelial membrane antigen (EMA), p53, and bcl-2 have all been advocated for differentiating reactive from neoplastic conditions, but reports are inconsistent. These antibodies have therefore been applied to 31 cases of malignant mesothelioma, 34 cases of reactive pleural disease (20 reactive mesothelial hyperplasia and 14 reactive pleural fibrosis) and four small biopsies that were initially coded as suspicious, from patients who later developed frank mesothelioma. Thirty out of 31 (97 per cent) cases of mesothelioma showed positive nuclear staining for p53, with a higher incidence of positivity in epithelioid than in sarcomatoid elements and 30/31 (97 per cent) showed diffuse linear membrane staining for EMA, again more intense in the epithelioid elements. No mesothelioma was positive for bcl-2. In seven cases that contained both in situ and invasive mesothelioma, the in situ elements showed similar staining patterns to the invasive epithelioid elements. Thirteen out of 20 (65 per cent) cases of reactive mesothelial hyperplasia showed occasional nuclear positivity for p53 and 5/20 (25 per cent) cases showed focal weak membrane staining for EMA. Three out of 14 (21 per cent) cases of reactive pleural fibrosis showed positive nuclear staining for p53 and 6/14 (43 per cent) cases showed focal membrane staining with EMA. No reactive cases stained for bcl-2. All four suspicious cases showed diffuse linear staining with EMA and three showed focal staining for p53. It is concluded that strong diffuse linear staining for EMA is a good marker of malignancy when differentiating epithelioid malignant mesothelioma and mesothelioma-in-situ from reactive mesothelial hyperplasia, although weak focal staining may occur in reactive conditions. Nuclear staining for p53 is also suggestive of epithelioid mesothelioma, but should be regarded as no more than suspicious. The antibodies used in this investigation are less helpful in differentiating sarcomatoid mesothelioma from reactive pleural fibrosis.


Subject(s)
Biomarkers, Tumor/metabolism , Mesothelioma/diagnosis , Neoplasm Proteins/metabolism , Pleura/pathology , Pleural Neoplasms/diagnosis , Diagnosis, Differential , Fibrosis , Humans , Hyperplasia/diagnosis , Mucin-1/metabolism , Pleura/metabolism , Proto-Oncogene Proteins c-bcl-2/metabolism , Retrospective Studies , Tumor Suppressor Protein p53/metabolism
11.
Thorac Cardiovasc Surg ; 47(1): 53-5, 1999 Feb.
Article in English | MEDLINE | ID: mdl-10218623

ABSTRACT

Spontaneous regression of non-small-cell lung carcinoma is extremely rare and there are few documented cases. We report a 59-year-old man with a right upper lobe tumour which showed progressive regression while hilar adenopathy appeared 2 months after the initial tumour detection. At operation, only scar tissue was found in the lung but a hilar lymph node contained large-cell undifferentiated carcinoma. This report indicates that a decrease in size of a pulmonary mass does not exclude the diagnosis of carcinoma and that metastatic disease can occur even if the primary tumour regresses.


Subject(s)
Carcinoma, Large Cell/physiopathology , Lung Neoplasms/physiopathology , Bronchoscopy , Carcinoma, Large Cell/diagnostic imaging , Carcinoma, Large Cell/pathology , Carcinoma, Large Cell/surgery , Fiber Optic Technology , Follow-Up Studies , Humans , Lung Neoplasms/diagnostic imaging , Lung Neoplasms/pathology , Lung Neoplasms/surgery , Lymphatic Metastasis , Male , Middle Aged , Pneumonectomy , Remission, Spontaneous , Tomography, X-Ray Computed
13.
Histopathology ; 33(3): 203-11, 1998 Sep.
Article in English | MEDLINE | ID: mdl-9777385

ABSTRACT

AIMS: Interstitial pneumonitis in children is very rare and most cases have been classified according to their counterparts in adults, although the term 'chronic pneumonitis of infancy' has recently been proposed for a particular pattern of interstitial lung disease in infants. We reviewed our paediatric cases of interstitial pneumonitis, first, to look at the spectrum of histological patterns found in this age group and, second, to determine whether the classification of such cases in childhood is both appropriate and worthwhile. METHODS AND RESULTS: Twenty-five of 38 open lung biopsies showed an overlapping spectrum of interstitial pneumonitis, including three cases that fulfilled the histological criteria for chronic pneumonitis of infancy. There were 11 cases of reactive pulmonary lymphoid hyperplasia (either lymphoid interstitial pneumonitis or follicular bronchiolitis), five of which were associated with abnormalities of the immune system. Four cases were classified as desquamative interstitial pneumonitis and the remaining seven cases were classified as nonspecific interstitial pneumonitis. There were no cases with the histological features of usual interstitial pneumonitis. Most patients responded to steroids but tended to have a residual deficit in lung function. Mortality appeared to be associated with presentation at a young age. CONCLUSION: Classification of interstitial pneumonitis according to their adult counterparts is appropriate for this younger age group and can provide valuable information for the clinician. The term 'chronic pneumonitis of infancy' refers to a specific histological pattern, but whether it represents a separate disease or a reflection of pulmonary immaturity remains to be proven.


Subject(s)
Lung Diseases, Interstitial/classification , Lung Diseases, Interstitial/pathology , Adolescent , Biopsy , Child , Child, Preschool , Female , Humans , Infant , Lung Diseases, Interstitial/immunology , Macrophages/immunology , Male
14.
Thorax ; 53(4): 323-5, 1998 Apr.
Article in English | MEDLINE | ID: mdl-9741380

ABSTRACT

Langerhans' cell histiocytosis may cause irreversible respiratory failure due to progressive destruction of lung parenchyma and widespread cystic change. Transplantation offers a therapeutic option. A case is described of recurrence of Langerhans' cell histiocytosis which was associated with deterioration in lung function four years following bilateral lung transplantation. Patients transplanted for Langerhans' cell histiocytosis should be followed up with this complication in mind.


Subject(s)
Histiocytosis, Langerhans-Cell/surgery , Lung Diseases/surgery , Lung Transplantation , Adult , Histiocytosis, Langerhans-Cell/drug therapy , Histiocytosis, Langerhans-Cell/physiopathology , Humans , Lung Diseases/drug therapy , Lung Diseases/physiopathology , Male , Recurrence , Tomography, X-Ray Computed
15.
16.
Thorax ; 52(6): 507-12, 1997 Jun.
Article in English | MEDLINE | ID: mdl-9227715

ABSTRACT

BACKGROUND: Malignant mesothelioma is a rare pleural tumour associated with asbestos exposure. The proportion of malignant mesothelioma unrelated to asbestos exposure, and any differentiating features between exposed and unexposed cases, are not well described. This study describes occupational, clinical, and pathological features in a large cohort of cases of malignant mesothelioma from south east England. METHODS: All 272 cases from this region were studied, either in life or after death when necropsy examination suggested malignant mesothelioma. Detailed information was gathered regarding the occupational history, clinical course, and mode of death. Necropsies were performed in 98% of cases. Lung tissue was examined histologically to confirm the diagnosis, subtype of tumour, presence or absence of asbestosis and asbestos bodies. RESULTS: Exposure to asbestos was documented in 87% of cases, while in the remainder, no asbestos exposure was found nor were asbestos bodies seen; 94.5% were pleural, 5.1% peritoneal, and 0.4% pericardial. Right sided tumours were more common than left sided tumours (ratio 1.6:1). Patients usually presented with breathlessness and chest pain, but 33% presented with pleural effusion in the absence of chest pain. The mean (SD) time from first exposure to asbestos to symptoms was 40 (12) years with a median (interquartile range (IQR) survival of 14 (12.5) months. The median (IQR) survival time in sarcomatous, epithelial, and mixed cell type malignant mesothelioma was 9.4 (10) months, 12.5 (18) months, and 11 (14) months, respectively, and was significantly greater in cases detected by chance. Clinical features were similar in asbestos related and non-asbestos related malignant mesothelioma. CONCLUSIONS: In south east England most cases of malignant mesothelioma are associated with asbestos exposure. Clinical features do not differentiate between asbestos related and non-asbestos related disease.


Subject(s)
Asbestos/adverse effects , Environmental Exposure , Mesothelioma/epidemiology , Occupational Diseases/epidemiology , Pleural Neoplasms/epidemiology , Adult , Aged , Aged, 80 and over , England/epidemiology , Female , Humans , Male , Mesothelioma/etiology , Middle Aged , Occupational Diseases/etiology , Pleural Neoplasms/etiology
17.
18.
Am J Respir Cell Mol Biol ; 16(2): 187-93, 1997 Feb.
Article in English | MEDLINE | ID: mdl-9032126

ABSTRACT

Endothelin-1 (ET-1) is a vasoconstrictor, bronchoconstrictor, and mitogenic peptide which is enzymatically converted from a biologically inactive big ET to mature ET (21 amino acid) by the ET-converting enzyme (ECE). Here, we investigate the expression of ECE-1, big ET-1, and ET-1 in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and compare it to those of normal subjects using immunohistochemistry and in situ hybridization. In normal lungs, focal moderate expression of all three molecules is localized to airway epithelium, pulmonary endothelium, and airway and vascular smooth muscle cells. Serous bronchial glands also expressed ET-1 and ECE-1. In IPF, strong diffuse expression of ECE-1 was seen in airway epithelium, proliferating type II pneumocytes, and in endothelial and inflammatory cells. ECE-1 immunostaining was colocalized to big ET-1 and ET-1 immunostaining, and correlated with disease activity (P < 0.05). To study regulatory mechanisms of ET-1 and ECE-1 expression, human normal bronchial epithelial (NBE) cells were treated with cytokines and analyzed by radioimmunoassay and Northern blot. Incubation of human NBE cells with IL-1alpha and -beta or tumor necrosis factor alpha (TNFalpha) resulted in a significant increase in ET-1 release and mRNA expression. TNFalpha resulted in a significant increase in ECE-1 mRNA expression. These findings demonstrated the colocalization of the precursor and active ET-1, and ECE-1 in the same cell, and that ECE-1 expression is elevated in IPF. In addition, increased expression of ET-1 and ECE-1 in IPF may be mediated by proinflammatory cytokines.


Subject(s)
Aspartic Acid Endopeptidases/metabolism , Endothelin-1/metabolism , Inflammation Mediators/metabolism , Pulmonary Fibrosis/metabolism , Aspartic Acid Endopeptidases/genetics , Blotting, Northern , Endothelin-1/genetics , Endothelin-Converting Enzymes , Female , Humans , Immunohistochemistry , Male , Metalloendopeptidases , Pulmonary Fibrosis/enzymology , RNA, Messenger/genetics , RNA, Messenger/metabolism , Radioimmunoassay
20.
Eur Respir J ; 9(10): 2022-5, 1996 Oct.
Article in English | MEDLINE | ID: mdl-8902461

ABSTRACT

Because pulmonary B-cell non-Hodgkin's lymphomas are now thought to arise in bronchial mucosa-associated lymphoid tissue (MALT), 45 patients with pulmonary B-cell lymphomas were reviewed to look for aetiological factors in the lung. It was found that six of the 45 lymphomas arose in patients with systemic autoimmune disease, which in three patients involved the lung. These three patients all had cryptogenic fibrosing alveolitis treated with long-term immunosuppressive therapy. Five of the six lymphomas were high grade and one was low grade. The association of pulmonary lymphomas with autoimmune interstitial lung disease is consistent with associations between autoimmune diseases and lymphomas presenting at other mucosal sites, and lends weight to the hypothesis that formation of bronchial mucosa-associated lymphoid tissue precedes the development of lymphoma.


Subject(s)
Autoimmune Diseases/complications , Lung Neoplasms/complications , Lymphoma, B-Cell/complications , Pulmonary Fibrosis/immunology , Adult , Aged , Autoimmune Diseases/drug therapy , Autoimmune Diseases/pathology , Bronchi/pathology , Female , Humans , Immunosuppressive Agents/administration & dosage , Immunosuppressive Agents/therapeutic use , Lung Neoplasms/pathology , Lymphoid Tissue/pathology , Lymphoma, B-Cell/pathology , Lymphoma, B-Cell, Marginal Zone/pathology , Lymphoma, Non-Hodgkin/complications , Lymphoma, Non-Hodgkin/pathology , Male , Middle Aged , Pulmonary Fibrosis/complications , Pulmonary Fibrosis/drug therapy , Pulmonary Fibrosis/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...